Dr. Richa Shukla
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical Branch at Galveston (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 294
Licensed in Texas since 2013, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Texas Medical Branch at Galveston
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
TX license P6083 (first issued 2013; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Harris Health Houston, TX
- Baylor St Lukes Medical Center Houston, TX
Medical groups
- Baylor College of Medicine (1,240 clinicians)
- Baylor College of Medicine (809 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 294
- Services billed
- 112,305
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, ocrelizumab, 1 mg | 8,700 | 12 |
| Injection, golimumab, 1 mg, for intravenous use | 4,750 | 11 |
| Injection, denosumab, 1 mg | 3,780 | 48 |
| Injection, infliximab, excludes biosimilar, 10 mg | 3,610 | 17 |
| Infusion, normal saline solution, 250 cc | 260 | 94 |
| Administration of chemotherapy into vein, 1 hour or less | 185 | 75 |
| Administration of chemotherapy into vein, each additional hour | 121 | 39 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 114 | 45 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 103 | 61 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 97 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Houston, TX | 49 |
| Stelara (ustekinumab) | 47 |
| Skyrizi On-Body (risankizumab-rzaa) | 26 |
| Rinvoq (upadacitinib) | 21 |
| Sulfasalazine Other prescribers in Houston, TX | 17 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Houston, TX | 17 |
| Mesalamine Other prescribers in Houston, TX | 16 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Houston, TX | 16 |
| Azathioprine Other prescribers in Houston, TX | 15 |
| Dicyclomine Hcl Other prescribers in Houston, TX | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 71 payments worth $29,855 in total to this clinician.
| AbbVie Inc. | $16,364 |
|---|---|
| Lilly USA, LLC | $12,901 |
| Janssen Biotech, Inc. | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | $114 |
| Intercept Pharmaceuticals, Inc. | $95.68 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.40 |
| Erbe USA Inc | $86.19 |
| Madrigal Pharmaceuticals | $22.35 |
| Compensation for services other than consulting (speaking, faculty) | $27,475 |
|---|---|
| Food and Beverage | $1,559 |
| Travel and Lodging | $822 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,025 |
| AbbVie Inc. Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $2,875 |
| AbbVie Inc. Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,875 |
| AbbVie Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,875 |
| Lilly USA, LLC May 14, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $2,500 |
| Lilly USA, LLC Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $2,500 |
| Lilly USA, LLC Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $2,500 |
| Lilly USA, LLC Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $2,200 |
| Lilly USA, LLC Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $1,250 |
| AbbVie Inc. Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,150 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,150 |
| Lilly USA, LLC Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $1,250 |
| Lilly USA, LLC Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $2,500 |
| Lilly USA, LLC Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $2,200 |
| Lilly USA, LLC Oct 23, 2025 | Travel and Lodging OMVOH · Immunology · travel to TAMPA, FL | $142 |
| Lilly USA, LLC Oct 15, 2025 | Travel and Lodging travel to TAMPA, FL · in-kind | $224 |
| AbbVie Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,875 |
| AbbVie Inc. Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,875 |
| Lilly USA, LLC May 14, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $2,500 |
| Lilly USA, LLC May 14, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $950 |
| AbbVie Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,025 |
| AbbVie Inc. Apr 17, 2025 | Travel and Lodging travel to CINCINNATI, OH · in-kind | $456 |
| AbbVie Inc. Mar 28, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $1,150 |
| Lilly USA, LLC Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $625 |
| Lilly USA, LLC Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $2,500 |
| AbbVie Inc. Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $2,875 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $81,057 in research payments for these studies, mostly to the institutions running them.
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC - A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development, LLC - A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company · Active, not recruiting · NCT04232553 - A phase 4 study evaluating real-world use of cdpath?, a crohn's disease risk prediction tool
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.